Tikva Allocell to Present Preclinical Lupus Therapy Data
The research will detail a potential lymphodepletion-free approach to CAR T-cell therapy for systemic lupus patients.
Updated on Oct. 22, 2026 in Biotech
Tikva Allocell will present preclinical research on November 10, 2026, regarding an armored allogeneic CD19 CAR T-cell therapy for systemic lupus erythematosus. The research details a potential lymphodepletion-free treatment approach currently in the preclinical stage.
Why it matters
This research explores a potential shift in autoimmune therapy by leveraging Epstein-Barr virus-specific T cells to avoid the need for lymphodepletion prior to treatment. If validated in future trials, this could offer a less invasive delivery mechanism for CAR T-cell therapies in systemic lupus patients.
The therapy platform uses Epstein-Barr virus-specific T cells—a subset of white blood cells programmed to target specific viral antigens—engineered with an optimized form of SerpinB9. This protein integration is designed to resist immune rejection, a key performance barrier for allogeneic, or donor-derived, cell therapies.
The players
Tikva Allocell
A Singapore-based biotechnology company focused on developing allogeneic T-cell therapies for cancer and autoimmune diseases.
Marvin Chew
A lead researcher or representative from Tikva Allocell who will deliver the oral presentation at the conference.
The details
Tikva Allocell integrates tumor-targeting receptors onto an allogeneic T-cell foundation to create its CAR T-cell therapy. The inclusion of SerpinB9—a protease inhibitor that prevents premature cell death—allows these engineered cells to persist in the body without the prior depletion of the patient's existing immune cells, known as lymphodepletion. This preclinical study focuses on applying this method specifically to systemic lupus erythematosus, an autoimmune condition where the immune system attacks its own tissues.
Timeline
November 6-11, 2026: ACR Convergence 2026 annual meeting dates.
November 10, 2026: Oral presentation of CD19.SB9.CAR-EBVST research from 1:00pm-1:15pm ET.
The Tech Race
This presentation at the ACR Convergence annual meeting follows a pattern set by industry leaders in autoimmune research to disclose early-stage data at major rheumatology forums. The data contributes to the broader race to develop off-the-shelf, or allogeneic, cell therapies that bypass the logistical requirements of patient-specific, or autologous, treatment manufacturing.
This development is currently in the preclinical stage and is not available for patient use or clinical application. Interested parties can monitor the results of the upcoming oral presentation to determine the timeline for potential human clinical trials.
The takeaway
This research highlights the effort to minimize treatment complexity in CAR T-cell therapies by eliminating the need for lymphodepletion. Observers should track the upcoming oral presentation on November 10, 2026, for specific preclinical performance metrics and timelines for potential Phase 1 trial entry.
Further reading
Learn more about the latest innovations in Biotech to understand how engineered cell therapies are evolving.
Source note: This article includes information reported by Firstwordpharma.
